Echo to Report Trial Results of Symphony tCGM System; Telik Reports Deal on Trial of Telintra Print E-mail
By Staff and Wire Reports   
Tuesday, 22 January 2013 20:06
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 22, 2013.

Echo Therapeutics, Inc. (Nasdaq: ECTE)
, a company developing its needle-free Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System as a non-invasive, wireless, transdermal continuous glucose monitoring system, presented an expanded analysis of data collected from the clinical study of Echo's Symphony tCGM System in critically ill patients at Tufts Medical Center in Boston, MA.  The data were presented during Display and Professor Walk Rounds on Sunday, January 20, 2013 at the Society of Critical Care Medicine's 42nd Critical Care Congress.

The poster, entitled "Accuracy of a Novel Non-Invasive Transdermal Continuous Glucose Monitor in Critically Ill Patients," presented by the principal investigator, Stanley A. Nasraway, M.D., FCCM, provided data from fifteen (15) patients who were undergoing elective cardiac surgery.  The patients' glucose levels were monitored continuously for 24 hours.  The key findings include:


Telik, Inc. (Nasdaq: TELK)
announced the completion of an End of Phase 2 meeting with the US FDA.  Preliminary agreement was reached regarding the design of a Phase 3 placebo-controlled randomized registration trial of Telintra (ezatiostat) for the treatment of Low to Intermediate-1 risk myelodysplastic syndrome (MDS), using red-blood-cell transfusion independence as the endpoint.  In accordance with the FDA's guidance, Telik plans to complete the design of the Phase 3 registration trial.  In order to focus its resources on the registration program, Telik has decided to stop further enrollment in its ongoing Phase 2 exploratory trials.

Telintra is an investigational agent in development for the treatment of MDS and idiopathic chronic neutropenia.  Telintra is a novel inhibitor of the enzyme glutathione S-transferase P1‑1, leading to activation of Jun kinase, a key regulator of cellular growth and differentiation of blood precursor cells.  Telintra has been shown to cause clinically significant and sustained reduction in red blood cell transfusions, transfusion independence and multilineage responses in MDS patients.  The results of four clinical trials of Telintra in MDS have been reported in peer-reviewed scientific journals.

Telintra has been granted orphan drug designation by the FDA for the treatment of myelodysplastic syndrome (MDS).  Orphan designation grants potential US market exclusivity to a drug for the treatment of a specified condition for a period of seven years following FDA marketing approval.

Also Tuesday:

ActiveCare, Inc. (OTCBB: ACAR)
, the service leader in disease and diabetes management reported revenues for the fiscal year ended September 30, 2012.

American Bio Medica Corporation (ABMC.PK)
today announced that they have entered into an agreement with Imperium Commercial Finance Master Fund LP (“Imperium”) that provides the Company with a secured revolving line of credit of up to $1.5 million for working capital and a $500,000 supplemental advance for new market opportunities.

Auctions International, Inc. (OTCPINK: AUCI)
is pleased to announce that it has received and accepted consents from Mr. Andrew McLaughlin and Mr. Richard Smith to join its board of directors.

Charles River Laboratories International, Inc. (NYSE: CRL)
will release fourth-quarter and full-year 2012 financial results on Wednesday, February 13th, after the market closes.

Galectin Therapeutics (NASDAQ: GALT)
, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease.

Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY)
, a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, announced today that two of its portfolio companies, ProtAb and Enlivex, have received approximately $700,000 in convertible loans from Hadasit Bio-Holdings and its partners.

Johnson & Johnson (NYSE: JNJ)
will present its Medical Devices & Diagnostics (MD&D) business strategy for accelerating growth during its annual Business Review today.

LifeApps Digital Media Inc. (OTCQB: LFAP)
, an emerging growth company and designer of apps and next-generation social networks for sports, health, fitness and entertainment enthusiasts, is pleased to announce its plans to exhibit at the 60th PGA Merchandise Show, January 24-26, 2013, in Orlando, Florida.

Life Technologies Corporation (NASDAQ: LIFE)
today announced its acquisition of BAC BV, a privately held company based in the Netherlands, and a leader in the discovery, development and manufacture of protein purification products.

Magellan Health Services Inc (NASDAQ: MGLN)
announced the results of an innovative substance abuse treatment program launched in 2010 called Magellan Integrated Substance Use Solutions.

Oramed Pharmaceuticals Inc. (OTCQB:ORMP)
(, a developer of oral drug delivery systems, announced today that its previously announced one for twelve reverse stock split has become effective.

Quture International, Inc. (OTCQB: QUTR)
announced today that they are postponing the previously scheduled shareholder conference call on Wednesday, January 23, 2013, at 4:15 p.m. Eastern Standard Time.

Sionix Corporation (OTCQB: SINX)
announced today that it has received a Notice of Allowance for U.S. Patent Application Number 13/029,970 -- "Dissolved Air Flotation System with Bubble Separation System and Method of Use." Sionix has now secured six U.S. patents related to its dissolved air floatation ("DAF") technology that are active, and one provisional patent dealing with water treatment.

Stevia First Corp. (OTCQB: STVF)
("Stevia First" or the "Company"), an early-stage agribusiness based in California's Central Valley growing region and focused on the industrial scale production of stevia, the all-natural zero-calorie sweetener that is rapidly transforming the food and beverage industry, is pleased to present the following letter from Mr. Robert Brooke, Company CEO.

TapImmune Inc. (OTCBB: TPIV)
is pleased to announce the January publication of a paper titled "Enzymatic Discovery of a HER-2/neu Epitope That Generates Cross-Reactive T-cells", authored by Henle et al,J.Immunol. (2013), 190, 479-488.

Telik, Inc. (Nasdaq: TELK)
announced the completion of an End of Phase 2 meeting with the US Food and Drug Administration (FDA).

TelVue Corporation (PINKSHEETS: TEVE)
Product Manager Madeleine Noland has been asked to chair an ad hoc group under the Advanced Television Systems Commitee (ATSC)'s new Technical Group 3 (TG3), which is tasked with drafting requirements for the future of television broadcasting.

Therapeutic Solutions International, Inc. (OTCQB: TSOI)
announced today that pursuant to the previously announced terms of an August 2012 agreement with James P. Boyd, the Company has reacquired 223,991,933 shares of Company common stock from Mr. Boyd and retired the shares, reducing its total number of outstanding shares from approximately 305.5 million to approximately 81.5 million.

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA)
, a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the fourth quarter of 2012 on Tuesday, February 12, 2013, before the market opens.

VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA)
, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced that Shawn K. Singh, CEO of VistaGen, will present at Noble Financial Capital Markets' Ninth Annual Equity Conference.

Z Trim Holdings, Inc. (OTC Markets: ZTHO)
, a bio-technology company providing value-added ingredients to a variety of industries, today announced that it has entered into a joint development agreement with Newpark Drilling Fluids LLC, a subsidiary of Newpark Resources, Inc. (NYSE: NR), to develop new, environmentally-friendly drilling fluids that incorporate Z Trim's proprietary industrial materials that could replace the likes of guar and xanthan gums in drilling applications.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus